Jessica A Zaman1, Neil Shah1, Glen E Leverson1, Jacob A Greenberg1, Luke M Funk2. 1. Department of Surgery, University of Wisconsin - Madison, 600 Highland Avenue, CSC K7/728, Madison, WI, 53792, USA. 2. Department of Surgery, University of Wisconsin - Madison, 600 Highland Avenue, CSC K7/728, Madison, WI, 53792, USA. funk@surgery.wisc.edu.
Abstract
BACKGROUND: Bariatric surgery is the most effective treatment for morbidly obese type II diabetics. However, guidelines for perioperative glucose control are not well established. We examined management of perioperative glucose levels in diabetic patients undergoing bariatric surgery and determined the impact of optimal glucose control as defined by the American Society for Metabolic and Bariatric Surgery (ASMBS) on patient outcomes, including long-term diabetes resolution. METHODS: A single-institution, retrospective analysis of 155 morbidly obese diabetic patients who underwent laparoscopic gastric bypass (RYGB) or sleeve gastrectomy (LSG) from 2010 to 2014 was performed. Inpatient finger-stick glucose levels were extracted from the electronic health record and defined as optimal if all values were <180 mg/dl. Ninety-day and one-year outcomes, including diabetes resolution, medication management, mortality and total costs were compared for patients with and without optimal control. RESULTS: 80 % (n = 124) of patients with type II diabetes underwent RYGB, while the remaining patients underwent LSG. Diabetes resolution at 1 year was 70.1 % (73.4 % for RYGB and 53.9 % for LSG, p = 0.191). Preoperatively, 72 % (n = 112) of patients were taking one or more oral antihyperglycemic agents, while only 50.3 % (n = 78) took an oral medication on discharge. 93 % of RYGB and 82 % of LSG patients, respectively, reduced their long-acting insulin dosage by greater than 50 % upon discharge (p = 0.251). Ninety-day and one-year outcomes including total costs were not improved by optimal perioperative glucose control. In total, 96.7 % of optimally controlled patients experienced diabetes resolution at 1 year compared to 53.2 % in the non-optimally controlled group (p < 0.001). CONCLUSION: Bariatric surgery leads to significant resolution of type II diabetes and a prompt improvement in glucose tolerance in the perioperative period. Optimal glucose control as defined by the ASMBS was not associated with improved postoperative outcomes in our patient population but was highly predictive of long-term diabetes resolution.
BACKGROUND: Bariatric surgery is the most effective treatment for morbidly obese type II diabetics. However, guidelines for perioperative glucose control are not well established. We examined management of perioperative glucose levels in diabeticpatients undergoing bariatric surgery and determined the impact of optimal glucose control as defined by the American Society for Metabolic and Bariatric Surgery (ASMBS) on patient outcomes, including long-term diabetes resolution. METHODS: A single-institution, retrospective analysis of 155 morbidly obese diabeticpatients who underwent laparoscopic gastric bypass (RYGB) or sleeve gastrectomy (LSG) from 2010 to 2014 was performed. Inpatient finger-stick glucose levels were extracted from the electronic health record and defined as optimal if all values were <180 mg/dl. Ninety-day and one-year outcomes, including diabetes resolution, medication management, mortality and total costs were compared for patients with and without optimal control. RESULTS: 80 % (n = 124) of patients with type II diabetes underwent RYGB, while the remaining patients underwent LSG. Diabetes resolution at 1 year was 70.1 % (73.4 % for RYGB and 53.9 % for LSG, p = 0.191). Preoperatively, 72 % (n = 112) of patients were taking one or more oral antihyperglycemic agents, while only 50.3 % (n = 78) took an oral medication on discharge. 93 % of RYGB and 82 % of LSG patients, respectively, reduced their long-acting insulin dosage by greater than 50 % upon discharge (p = 0.251). Ninety-day and one-year outcomes including total costs were not improved by optimal perioperative glucose control. In total, 96.7 % of optimally controlled patients experienced diabetes resolution at 1 year compared to 53.2 % in the non-optimally controlled group (p < 0.001). CONCLUSION: Bariatric surgery leads to significant resolution of type II diabetes and a prompt improvement in glucose tolerance in the perioperative period. Optimal glucose control as defined by the ASMBS was not associated with improved postoperative outcomes in our patient population but was highly predictive of long-term diabetes resolution.
Entities:
Keywords:
Bariatric surgery; Perioperative glucose; Type II diabetes
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Margarita Ramos; Zain Khalpey; Stuart Lipsitz; Jill Steinberg; Maria Theresa Panizales; Michael Zinner; Selwyn O Rogers Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Erik Stenberg; Eva Szabo; Göran Agren; Erik Näslund; Lars Boman; Ami Bylund; Jan Hedenbro; Anna Laurenius; Göran Lundegårdh; Hans Lönroth; Peter Möller; Magnus Sundbom; Johan Ottosson; Ingmar Näslund Journal: Ann Surg Date: 2014-12 Impact factor: 12.969
Authors: Wiebke K Fenske; Dimitri J Pournaras; Erlend T Aasheim; Alexander D Miras; Nicola Scopinaro; Samantha Scholtz; Carel W le Roux Journal: Obes Surg Date: 2012-01 Impact factor: 4.129
Authors: Michał Wysocki; Maciej Walędziak; Hady Razak Hady; Mikołaj Czerniawski; Monika Proczko-Stepaniak; Michał Szymański; Natalia Dowgiałło-Wnukiewicz; Piotr Kozera; Jacek Szeliga; Michał Orłowski; Michał Pędziwiatr; Magdalena Szopa; Andrzej Budzyński; Piotr Major Journal: Obes Surg Date: 2019-09 Impact factor: 4.129